By applying combinational treatment with Food and Drug Administration (FDA)-approved PI3K inhibitor copanlisib and Wnt pathway inhibitor mebendazole to EBVaGC cells, we observed a significant inhibitory effect and confirmed the synergistic function of the PI3K-Akt and Wnt pathways in EBV infection and co-expansion. The gene discussed is AKT1; the disease is Epstein-Barr virus infection.